Pharmacogenetics of the B-type Natriuretic Peptide Pathway

B 型利钠肽途径的药物遗传学

• 批准号: 8082653
• 负责人: David E Lanfear
• 金额: $ 12.64万
• 依托单位: HENRY FORD HEALTH SYSTEM
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-06-01 至 2013-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8082653
• 关键词: Acute; Adverse event; Area; Biology; Brain natriuretic peptide; Candidate Disease Gene; Cardiovascular system; Caring; Clinical; Data; Decision Modeling; Diagnostic; Drug Kinetics; Endopeptidases; Future; Gene Expression; Genes; Genetic; Genetic Polymorphism; Genomics; Genotype; Goals; Haplotypes; Heart failure; Human; Immunohistochemistry; Individual; Intravenous; Journals; Kidney; Literature; Measures; Mediating; Mentors; Mentorship; Metabolism; Motivation; Natriuretic Peptides; Outcome; Pathway interactions; Patients; Peptide Receptor; Pharmaceutical Preparations; Pharmacodynamics; Pharmacogenetics; Pharmacotherapy; Prediction of Response to Therapy; Proteins; Public Health; Publications; Publishing; Reaction; Recombinants; Research; Research Design; Research Personnel; Research Project Grants; Research Training; Risk; Scientist; System; Techniques; Therapeutic; Therapeutic Agents; Time; Tissue Sample; Toxic effect; Training; Training Programs; Translational Research; Treatment Efficacy; Validation; Variant; Work; abstracting; atrial natriuretic factor receptor A; base; cGMP production; career; cellular targeting; clinical efficacy; experience; follow-up; genetic variant; genome-wide; human tissue; improved; intravenous administration; knowledge base; prognostic; programs; research study; response; skills; skills training; statistics; tool

DESCRIPTION (provided by applicant): The purpose of this application is to create a research and training program which will allow Dr. Lanfear to develop into an independent clinician-scientist with translational research projects focused on cardiovascular pharmacogenetics. The proposed program will accomplish this goal through completion of the research sroject, technical skills training, didactic coursework focused on genome-wide techniques, and outstanding mentorship. The overall strengths of the proposal are further supported by the quality of the applicant and the relevance and scientific merit of the research project. The applicant has clinical expertise in heart failure [HF), experience in genotyping, advanced training in study design and statistics (culminating in an M.S.), and has shown focus and motivation through successfully completing projects and publishing the results in reputable journals. He would greatly benefit from the proposed coursework in array-based genomic techniques as well as the skills gained via execution of the research project. The research project will enhance his technical skills, allow mentoring, and will generate data for publication and justification of future experiments. It focuses on HF which continues to be an enormous public health problem despite many advances in pharmacotherapy over the past 25 years. There are currently insufficient tools to guide the optimal selection of drug therapy for individuals. The expansion of human genomic information has led to exciting new opportunities for pharmacogenetics to improve drug therapy. One of the most exciting new areas in HF is the natriuretic peptide system. B-type Natriuretic Peptide (BMP) has diagnostic and prognostic importance in HF and is a commercially available therapeutic agent for acute HF exacerbations. Despite its beneficial effects, BMP therapy has several limitations; it is intravenous, expensive, and has potential toxicities. The goal of this project is to define genetic predictors of the efficacy and toxicity of intravenously administered BMP. A candidate gene approach will be taken and sequence data will be correlated with pharmacokinetic, pharmacodynamic, and clinical response parameters. As a mechanistic validation the association of sequence variants with expression level of the candidate genes and quantity of protein products will be assessed in human kidney tissue samples. The overall program will not only define functional predictive variants, but will advance the candidate's career while setting the ground work for follow-up studies of pharmacogenetically directed BNP therapy. (End of Abstract)

描述（由申请人提供）：本申请的目的是创建一个研究和培训计划，该计划将使Lanfear博士能够发展为独立的临床医生 - 科学家，其转化研究项目的重点是心血管药物遗传学。拟议的计划将通过完成研究Sroject，技术技能培训，专注于全基因组技术的教学课程以及出色的指导来实现这一目标。该提案的总体优势得到了申请人的质量以及研究项目的相关性和科学功绩。申请人在心力衰竭[HF），基因分型，研究设计和统计学的高级培训方面具有临床专业知识（最终在M.S.中），并通过成功完成项目并在信誉良好的期刊上发布结果表现出了重点和动力。他将从基于阵列的基因组技术中的拟议课程以及通过执行研究项目获得的技能中受益匪浅。该研究项目将提高他的技术技能，允许指导，并生成数据以发布和对未来实验的理由。尽管在过去25年中，尽管在药物治疗方面取得了许多进步，但它仍关注HF，这仍然是一个巨大的公共卫生问题。目前没有足够的工具来指导个体的最佳药物治疗选择。人类基因组信息的扩展为药物遗传学改善药物治疗带来了令人兴奋的新机会。 HF中最令人兴奋的新领域之一是Natriuretic肽系统。 B型亚替肽肽（BMP）在HF中具有诊断和预后的重要性，并且是一种可用于急性HF加重的市售治疗剂。尽管有有益的作用，BMP疗法仍有几个局限性。它是静脉注射，昂贵的，并且具有潜在的毒性。该项目的目的是定义静脉内给予BMP的疗效和毒性的遗传预测因子。将采用候选基因方法，序列数据将与药代动力学，药效和临床反应参数相关。作为机械验证，将在人类肾脏组织样品中评估序列变体与候选基因表达水平和蛋白质产物数量的关联。整个计划不仅将定义功能性预测变体，而且还将推动候选人的职业生涯，同时为药物遗传学定向的BNP疗法的后续研究设定地面工作。 （抽象的结尾）